Brief: Arcutis And Padagis Agree To Stay Patent Lawsuit
02/04/2025 20:29
April 2 (Reuters) - Arcutis Biotherapeutics Inc ARQT.O: ARCUTIS AND PADAGIS AGREE TO STAY PATENT LAWSUIT ARCUTIS BIOTHERAPEUTICS: PADAGIS TO REPORT TO CO ANY FDA CORRESPONDENCE ABOUT ANDA FOR THEIR GENERIC ALTERNATIVE TO ZORYVE CREAM 0.3% Source text: ID:nGNX8Jts1x Further company coverage: ARQT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arcutis Biotherapeutics
See all newsBrief: Arcutis Biotherapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4
Arcutis Q1 product revenue rises 65% yr/yr, net loss narrows
Brief: Arcutis Announces Promotion Of MAS Matsuda To Executive Vice President And Chief Legal Officer To Support Next Phase Of Growth
Brief: Arcutis Begins Enrolling Phase 1A/1B Study Evaluating Arq-234, A Cd200r Agonist, In Healthy Volunteers And Adults With Atopic Dermatitis
Brief: Arcutis Biotherapeutics Inc Files For Mixed Shelf